NCT07141095View on ClinicalTrials.gov

A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection

Not yet recruitingOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

January 31, 2027

Conditions
Infections, Cytomegalovirus
Interventions
DRUG

maribavir

Maribavir tablets are administered orally at a dose of 0.4 g per administration (2 tablets of 0.2 g each), twice daily. The recommended duration of treatment is 8 weeks; however, the specific treatment duration should be individualized based on the clinical characteristics of each patient.

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT07141095 - A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection | Biotech Hunter | Biotech Hunter